USA chooses Vir to help prepare for future infectious diseases

5 October 2022

The US Government has expressed a vote of confidence in Vir Biotechnology (Nasdaq: VIR), awarding the company a multi-year contract to advance the development of a full portfolio of innovative medicines.

The investment, which could be worth up to $1 billion, comes via the Biomedical Advanced Research and Development Authority (BARDA), and represents part of the government's attempt to prepare the country for future pandemics.

Vir will use its technologies and know-how to prepare a pipeline of solutions for both flu and other infectious diseases, with an initial investment of $55 million being used to speed up development of VIR-2482.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK